title: Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
authors.affiliation: Department of Haematology, Imperial College London, Hammersmith Hospital, London,UK.
authors.forename: Pratap
authors.initials: P
authors.lastname: Neelakantan
authors.forename: David
authors.initials: D
authors.lastname: Marin
authors.forename: Mike
authors.initials: M
authors.lastname: Laffan
authors.forename: John
authors.initials: J
authors.lastname: Goldman
authors.forename: Jane
authors.initials: J
authors.lastname: Apperley
authors.forename: Dragana
authors.initials: D
authors.lastname: Milojkovic
mesh_terms: D001792:Blood Platelets / Q000187:drug effects / Q000473:pathology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011724:Pyridazines / Q000494:pharmacology*
chemical_list: D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D016044:Fusion Proteins, bcr-abl